Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis | Zendy

Nathan P. Wiederhold | Zendy; Laura Kovanda | Zendy; Laura K. Najvar | Zendy; Rosie Bocanegra | Zendy; Marcos Olivo | Zendy; William R. Kirkpatrick | Zendy; Thomas F. Patterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis

Author(s) -

Nathan P. Wiederhold,

Laura Kovanda,

Laura K. Najvar,

Rosie Bocanegra,

Marcos Olivo,

William R. Kirkpatrick,

Thomas F. Patterson

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00229-16

Subject(s) - cryptococcal meningitis , cryptococcus neoformans , fluconazole , cryptococcosis , cryptococcus , meningitis , mycosis , medicine , antifungal , biology , microbiology and biotechnology , immunology , human immunodeficiency virus (hiv) , surgery , viral disease

We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with eitherCryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research